Skip to main content
. 2022 Jan 31;28(4):214.e1–214.e11. doi: 10.1016/j.jtct.2022.01.019

Figure 2.

Figure 2

Differences in antibody responses between the allo-HCT recipients and healthy controls. (A) Dynamics of binding IgG response against the SARS-CoV-2 antigens RBD and S1, represented as SOC values, in allo-HCT recipients stratified by time between transplantation and vaccination (dark blue, 3 to 6 months; yellow, 6 to 12 months; light blue, >12 months) and healthy controls (gray). Preinfected individuals are represented by triangles and dashed lines. (B-E) Boxplots showing sum S1 reactivity in allo-HCT recipients stratified by time between transplantation and vaccination (dark blue, 3 to 6 months; yellow, 6 to 12 months; light blue, >12 months) and healthy controls (gray) at different time points: (B) T1, 1 month post-first dose; (C) T2, 1 month post-second dose; (D) T3, 3 months post-second dose; and (E) T4, 6 months post-second dose. The dashed line corresponds to a sum S1 of 17. Preinfected individuals are represented by triangles. Results from the Wilcoxon test used to compare each group to the other groups are shown. *P < .05; **P < .01; ***P < .001. (F) Longitudinal sum S1 response since the second dose and decline prediction obtained from a single exponential decline model. Each line corresponds to 1 patient, color-coded by group (dark blue, 3 to 6 months; yellow, 6 to 12 months; light blue, >12 months; gray, healthy controls). Preinfected individuals are represented by triangles and dashed lines. The solid line corresponds to the estimated marginal mean of the non-preinfected vaccinated individuals in each group, and the shaded area corresponds to the 95% CI of the prediction.